Bli medlem
Bli medlem

Du är här

2016-10-20

NANOBIOTIX: Nanobiotix's partner, PharmaEngine, has launched a new NBTXR3 clinical trial in head and neck cancers in Asia

Nanobiotix's partner, PharmaEngine, has launched a new NBTXR3 clinical trial
in head and neck cancers in Asia

Seventh clinical trial with NBTXR3 in a new population of patients with head
and neck cancers treated with radiotherapy plus chemotherapy

Paris, France, and Cambridge, Massachusetts, USA, October 20, 2016 -
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205)
, a late clinical-stage nanomedicine company pioneering novel approaches for
the local treatment of cancer, today announced that its Asia-Pacific partner,
PharmaEngine, has dosed its first patient in a new Phase I/II trial in
patients with head and neck cancers patient receiving radiotherapy plus
chemotherapy, this October. The trial is evaluating the optimal dose, safety
and preliminary efficacy of Nanobiotix's lead product.

PharmaEngine has broadened its development plan for NBTXR3 by launching this
new trial in Asia targeting a new and larger head and neck cancer patient
population. This follows the successful results from the European Phase I/II
trial in patients with head and neck cancers presented in July 2016 by
Nanobiotix demonstrating promising signs of tumor volume response and
excellent signs of safety.

NBTXR3 is now addressing a wide range of head and neck cancers patients. The
study in Asia by PharmaEngine addresses patients receiving chemotherapy
(cisplatin) plus radiotherapy whereas the study in Europe by Nanobiotix
covers patients which are not eligible for chemotherapy plus radiotherapy and
only receive radiotherapy.

Head and neck cancers include cancers of the oral cavity, tongue and
oropharynx. These cancers are a major concern for public health, with a high
worldwide prevalence, particularly in Asia, where the patient population is
expanding.

This joint approach by Nanobiotix and PharmaEngine supports the preparation of
a development plan for head and neck cancers registration studies with NBTXR3
potentially in Europe, in the US and in Asia. Nanobiotix will provide this
next year.

Laurent Levy, CEO of Nanobiotix commented:"This seventh trial opens
significant potential market opportunities for
NBTRX3 by broadening the potential treatable population of head and neck
cancer patients for whom NBTXR3 may significantly improve quality of life."

-Ends-
About the PharmaEngine Head and Neck Phase I/II Trial in Asia

This new trial is an open-label, single arm, non-randomized study for patients
with head and neck cancers. The primary objectives of the study are to
determine the optimal dose, safety and preliminary efficacy of NBTXR3 through
intra-tumor injection in combination with concurrent chemoradiotherapy
(CCRT). The first patient was injected with NBTXR3 in October 2016 and the
maximum number of patients that will be enrolled in the study is 42.
About Nanobiotix and PharmaEngine Partnership

PharmaEngine has a licensing agreement with Nanobiotix for the development and
commercialization of Nanobiotix's lead product, NBTXR3, in Asia-Pacific. As
part of this agreement, Nanobiotix has already received upfront payments and
milestone payments.
The Company is eligible to receive further development and commercialization
milestone payments. Collectively, these payments may amount to a total of
US$56 million plus tiered, up to double-digit royalties on all net product
sales in the Asian-Pacific region.
About NANOBIOTIX -
www.nanobiotix.com

Nanobiotix (Euronext: NANO / ISIN: FR0011341205) is a late clinical-stage
nanomedicine company pioneering novel approaches for the local treatment of
cancer. The Company's first-in-class, proprietary technology, NanoXray,
enhances radiotherapy energy with a view to provide a new, more efficient
treatment for cancer patients.
NanoXray products are compatible with current radiotherapy treatments and are
meant to treat potentially a wide variety of solid tumors including soft
tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast
cancer, glioblastoma, etc., via multiple routes of administration.

Nanobiotix's lead product NBTXR3, based on NanoXray, is currently under
clinical development for soft tissue sarcoma, head and neck cancer, prostate
cancer, and liver cancers (HCC and liver metastases) as well as head and neck
and rectal cancers under trial by PharmaEngine. The Company has filed in
August 2016 for market approval (CE Marking) in Europe for its lead product
NBTXR3. The Company has partnered with PharmaEngine for clinical development
and commercialization of NBTXR3 in Asia.

Nanobiotix is listed on the regulated market of Euronext in Paris (ISIN:
FR0011341205, Euronext ticker: NANO, Bloomberg: NANO: FP). The Company
Headquarter is based in Paris, France. Affiliate in Cambridge, United States.

Contact

-----------------------------------------------------------------------------------------------------------------------
| Nanobiotix |
| Sarah Gaubert |
| |
|Head of Communication and Public Affairs |
|+33 (0)1 40 26 07 55 |
|contact@nanobiotix.com |
| Media relations |
| France -Springbok EU Outside France -Instinctif Partners United States -The Ruth Group |
| |
|Marina Rosoff Melanie Toyne Sewell Kirsten Thomas / Chris Hippolyte |
| |
|+33 (0)6 11 58 00 34 +44 (0) 207 457 2020 +1 508-280-6592 / +1 646-536-7023 |
|marina@springbok.fr nanobiotix@instinctif.com Nanobiotix@theruthgroup.com |
-----------------------------------------------------------------------------------------------------------------------
Disclaimer

This press release contains certain forward-looking statements concerning
Nanobiotix and its business. Such forward-looking statements are based on
assumptions that Nanobiotix considers to be reasonable. However, there can be
no assurance that the estimates contained in such forward-looking statements
will be verified, which estimates are subject to numerous risks including the
risks set forth in the
reference document of Nanobiotix filed with the French Financial Markets
Authority (Autorité des Marchés Financiers) under number D.16-0732 on July
22, 2016
(a copy of which is available on www.nanobiotix.com) and to the development of
economic conditions, financial markets and the markets in which Nanobiotix
operates. The forward-looking statements contained in this press release are
also subject to risks not yet known to Nanobiotix or not currently considered
material by Nanobiotix. The occurrence of all or part of such risks could
cause actual results, financial conditions, performance or achievements of
Nanobiotix to be materially different from such forward-looking statements.

This press release and the information that it contains do not constitute an
offer to sell or subscribe for, or a solicitation of an offer to purchase or
subscribe for, Nanobiotix shares in any country.

---------------------------------------

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: NANOBIOTIX via Globenewswire

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.